Member Info for Globex

This Is Money link should be this, had linked to an earlier mail story instead there (it's a particularly glowing report): https://www.thisismoney.co.uk/money/comment/article-12564451/MAGGIE-PAGANO-Britains-brilliant-biotech-champion-shines.html

Sharing these links as I've seen it incorrectly posted a few times there hasn't been anything in the news. For the proper media this only leaves Telegraph, Guardian and BBC so if anyone has any contacts with those it would be great to see them report on the company too.

Daily Express https://www.express.co.uk/life-style/health/1816053/game-changing-prostate-cancer-test

Daily Mail https://www.dailymail.co.uk/health/article-12564283/New-blood-test-detect-prostate-cancer-available-Britain.html

The Times https://www.thetimes.co.uk/article/oxford-biodynamics-given-boost-by-prostate-cancer-screening-test-qw0n32sss

This Is Money https://www.dailymail.co.uk/health/article-11724915/New-blood-test-93-accurate-spotting-signs-prostate-cancer-study-says.html

+from earlier in year following the company's earlier successful study

Independent https://www.independent.co.uk/news/science/prostate-cancer-blood-test-diagnosis-b2277475.html

ITV News https://www.itv.com/news/2023-02-07/new-blood-test-for-prostate-cancer-is-94-accurate-researchers-say

Evening Standard https://www.standard.co.uk/tech/science/oxford-biodynamics-imperial-college-nhs-prostate-cancer-b1058671.html

These sorts of news vacuums are perfect conditions for the void to be filled by every man and his dog claiming this is over. Doesn't help that market never likes uncertainty. Into that atmosphere people get panicked out of their shares.

Yes this is high risk but bigger picture this remains a tier 1 asset when in production capable of generating $500m+ revs annually. We know there's a funding shortfall, but there are some big players with a ton of skin in the game who are not going to roll over as easily as some would hope.

The equity value is now too low for a raise to be feasible, so imo they simply get a new finance package put together, secured against the assets. Once news lands to that effect, we're back in business.

I know it's easier said than done but I would suggest this is one of those shares you need to zone out for the daily fluctuations and look at bigger picture. We've tripled in a short space of time so are still in price discovery mode, the volatility is to be expected. The swings don't mean anything can be concluded about what IIs might/might not be doing no matter what might be claimed on here.

Interesting analysis suggesting that ex-management costs the funding shortfall could be as little as ~$52 million. Bears will probably disagree but it's better reasoned than vast majority of end is nigh posts on here.

Even if it wasn't too late they mean acquiring much smaller firms than Pendragon, who have a larger enterprise value than Vertu. I do think Vertu are value now incidentally, as final listed dealer to be taken out can only be a matter of time before they receive a bid themselves.

After all the drama leading up to today it's been remarkably stable since 10am, now panicked sellers cleared out appears to have consolidated nicely in 22-23p range, could be a decent springboard.

Guys best to filter this disgusting wasteman. Anyone presenting misinformation about cancer is subhuman and not worthy of your time.

Don't fret guys, this isn't a share you trade with but one you simply buy and hold for as long as possible. The short term volatility in either direction will always attract the 'eccentrics' of these boards but ultimately it's really meaningless. What really matters is what the company are doing, and imo so far it's sensational.

Publican even though you've unnecessarily tried to single me out, yes I'm "just a trader" when it comes to pre-revenue miners, so what? There are no rules that say only bagholders are allowed to comment here.

I happen to know you lost your shirt on Rambler and now here too, I'm sorry that you lost most of your savings. Surely now would be a good time to show a bit of humility. Presenting yourself as some kind of expert isn't working when the only thing you're an expert in is buying high and selling low.

So far a similar pattern to yesterday, systematic selling for first couple of hours followed by levelling out. We can probably expect more TR1s from index funds like Fidelity who have had to rebalance but anybody panicked by those shouldn't really be in this game. Once the seller retreats could start to reverse as quickly as yesterday - having fallen so far so quickly there is absolutely no resistance.

It must be a very difficult share to deramp, very icky to be posting misinformation about work of a team of British scientists that have developed a breakthrough blood test for the cancer that is one of the biggest killers of men worldwide. Makes me feel queasy thinking about it, they must be so disgusted with themselves.

Fidelity are primarily index fund managers, if a share price goes down/up they simply algorithmically rebalance accordingly.

Just wait until the FDA give this the official nod, that's when we go truly stratospheric.

Best part is they are already accredited in the US and were actually awarded a grant by the Foundation for the National Institutes of Health (FNIH) - which itself is part funded by the FDA.

That 1242 was confirmed for September in the end. Meanwhile they seem to be really embracing for this derisk strategy, still selling off chunky proportion and now hedging facility. Frankly I'd rather see them go more balls to the wall especially now cashflow must be improving with bond payment. https://ir.mara.com/news-events/press-releases/detail/1327/marathon-digital-holdings-announces-bitcoin-production-and

One way him selling off the buildings would actually benefit THG would be the company then being able to deal with a neutral commercial landlord. When leases came up for renewal they'd be free to negotiate better terms. The company can't do that at the moment because they're effectively dealing with their own boss.

Removing this conflict of interest would probably make it more palatable to the market.

They just raised 8 weeks ago and are fully funded for the foreseeable including for lab expansion. This management team are in a different league from your usual because they put have put their own money in many times including as recently as August. Unusually, they've also only ever raised at a premium - so placing higher than market price.

Impossible to say the loan/value ratio, like the rest of his portfolio he holds them in a Guernsey based holding company for tax purposes, Channel Islands notoriously opaque.

An analysis of IPO documents by Guardian suggested entire portfolio he took valued at £297m at 2021 prices, so agree it's fair to say one leveraged warehouse won't hit the sides for the mythical MBO.

https://www.theguardian.com/business/2022/jan/11/matthew-moulding-the-curious-case-of-thg-founders-property-deals

Interestingly Hedin's shareholding still makes them kingmaker here, even if they've proven as flakey in committing to their bid as last time. Curious as to why they pulled out, could well be they couldn't secure funding in time rather than not liking what they saw under the bonnet.

Lithia again now have to be odds on favourite. Assuming they're successful and then they make it past CMA approval / due diligence, will definitely look to re-enter ex-div. Once this becomes a software only firm, with their US network backing believe that higher margin business really has potential.